A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration

Acta Ophthalmol. 2014 Dec;92(8):e691-2. doi: 10.1111/aos.12471. Epub 2014 Jun 22.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Administration, Topical
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Contrast Sensitivity / drug effects
  • Contrast Sensitivity / physiology
  • Exudates and Transudates
  • Humans
  • Infliximab
  • Ophthalmic Solutions
  • Tumor Necrosis Factor-alpha
  • Visual Acuity / drug effects
  • Visual Acuity / physiology
  • Wet Macular Degeneration / drug therapy*
  • Wet Macular Degeneration / physiopathology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Ophthalmic Solutions
  • Tumor Necrosis Factor-alpha
  • Infliximab